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Abstract: We showed that muramyl dipeptide
(MDP) conjugated to maleylated bovine serum
albumin (MBSA) was internalized by macrophages
(Mf) through scavenger receptor (SCR)-mediated
endocytosis, which leads to 50-fold higher cyto-
toxic activity against non-Mf tumor cells com-
pared with that elicited by free MDP-treated Mf.
The enhanced cytotoxic effect of MBSA-MDP was
found to be a result of higher secretion of interleu-
kin (IL)-1, IL-6, tumor necrosis factor a (TNF-a),
and nitric oxide (NO) because the addition of
antibodies directed against IL-1, IL-6, or TNF-a in
combination with Mf cultures totally abrogated the
tumoricidal activity of MBSA-MDP. It is interesting
to note that MBSA-MDP triggers the secretion of
IL-12, whereas IL-10, a Mf suppressor cytokine,
could be detected only on free MDP treatment. The
cytotoxic activity of MBSA-MDP was inhibited by
indomethacin, indicating a regulatory role for pros-
taglandin E2 (PGE2). Efficient SCR-mediated intra-
cellular delivery of MDP leading to elimination of
cancer cells suggests the immunotherapeutic poten-
tial of this approach for treatment of neoplasia. J.
Leukoc. Biol. 67: 683–690; 2000.
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INTRODUCTION
Activated macrophages play an important role in host defense
against primary and metastatic cancers. Modulation of macro-
phage (Mf) metabolism to an activated tumoricidal state is
therefore an attractive alternative to conventional chemother-
apy [1]. Immunomodulatory compounds such as interferons,
interleukins, colony-stimulating factors, and bacterial products
like muramyl dipeptide (MDP) and trehalose dimycolate have
been reported to augment the tumoricidal activity of macro-
phages [2–5]. Recombinant cytokines in combination with
tumor-specific antigens have been used to boost the antitumor
immune response based mainly on T lymphocyte activation
[4, 5]. Among the biological response modifiers, MDP is the
smallest biomolecule possessing immunoregulatory activity
[3, 6, 7]. Though a powerful inducer of the antitumor activity of
macrophages, MDP is quickly eliminated from the body,
thereby limiting its therapeutic utility [8]. Liposomes or soluble
carrier systems based on mannosylated neoglycoproteins, acety-
lated low-density lipoprotein, gelatin, as well as antibodies
against Mf surface antigens have been used to enhance the
therapeutic efficacy of MDP with some degree of success
[9–13]. However, the mechanism of activation of tumoricidal
properties of Mf in such targeting regimens is not clear.
We have previously demonstrated that scavenger receptor
(SCR)-mediated intracellular delivery of conjugates of the
anticancer agent daunomycin with maleylated bovine serum
albumin (MBSA) elicits selective toxicity toward neoplastic
cells of Mf lineage, whereas the receptor-negative cells
remained unaffected both in vitro and in vivo [14–16]. To
generalize the use of the receptor system in combating neo-
plasms of diverse origin, intracellular delivery of biological
response modifiers was envisaged. We report in this investiga-
tion that SCR-mediated intracellular delivery of MDP activates
Mf anti-tumor activity by triggering the secretion of cytokines
and other soluble mediators leading to elimination of cancer
cells.
MATERIALS AND METHODS
Materials
N-acetyl muramyl L-alanyl D-isoglutamine was procured from Fluka Chemika
Bio-Chemika (Switzerland). Bovine serum albumin (BSA), monensin, fucoidin,
polyinosinic acid, polyguanilic acid, polycytidilic acid, fetuin, maleic anhy-
dride, gentamicin, and fluorescein isothiocyanate (FITC)-labeled antibodies
were purchased from Sigma Chemical (St. Louis, MO). Enzyme immunoassay
(EIA) kits for the detection of interleukins were procured from Genzyme
Diagnostics (Cambridge, MA). The EIA system for detection of prostaglandin
E2 (PGE2), [3H]dThd, and Na125I were purchased from Amersham International
(Amersham, UK). Pyrochek-Cal, endotoxin detection kit containing amebocyte
lysate, was purchased from Manukirti Biogems (Bangalore, India). Other
reagents used were of analytical grade. The animals used in this study were
obtained from the Small Animal Facility of the Institute and were in good health
without any apparent infection as routinely tested.
Correspondence: Dr. Amitabha Mukhopadhyay, National Institute of Immu-
nology, Aruna Asaf Ali Marg, New Delhi 110067, India. E-mail:
amitabha@nii.res.in
Received August 10, 1999; revised November 20, 1999; revised December
30, 1999; accepted January 3, 2000.
Journal of Leukocyte Biology Volume 67, May 2000 683
Cells
J774A.1, L929, and B16F10 cell lines were obtained from American Type
Culture Collection and maintained in RPMI 1640 and Dulbecco’s modified
Eagle’s medium (DMEM; Life Technologies, Grand Island, NY) with 10%
heat-inactivated fetal bovine serum and gentamicin (50 µg/mL). Peritoneal
resident cells were harvested from 8-week-old normal healthy C57BL/6 mice
by intraperitoneal injection of 8–10 mL of 10 mM phosphate-buffered saline
(PBS), pH 7.2, and draining the peritoneal fluid by gravity with an 18-gauge
needle. Subsequently, cells were washed twice and seeded on plastic Petri
dishes in RPMI 1640 medium supplemented with 10% fetal calf serum and
gentamicin for 2 h at 37°C. Nonadherent cells were removed by washing with
PBS. Adherent cells were also removed from the plates by treatment with
chilled 1 mM EDTA, counted, and plated in six-well plates at a density of 1 3
106 cells per well or in 96-well plates at a density of 2 3 105 cells per well. Cells were
maintained at 37°C in a humidified incubator with 5% CO2 and 95% air.
Preparation of MBSA-MDP conjugates
MDP was conjugated to BSA by using water-soluble carbodiimide in the
presence of N-hydroxysulfosuccinimide (sulfo-NHS). Briefly, 10 mg of the MDP
was incubated in the presence of 3.6 mg of EDC and 3.2 mg of sulfo-NHS in 0.1
mL of water for 10 min at room temperature to generate an active ester of MDP.
Subsequently, activated MDP was reacted with 10 mg of BSA in 0.2 M sodium
carbonate buffer, pH 9.5, for 1 h at room temperature. BSA-MDP conjugate was
purified through Sephadex G25 column chromatography, and purified conju-
gate was maleylated with maleic anhydride at a pH of 8.0 as described [17].
MBSA-MDP conjugate was separated from the residual small molecules by
extensive dialysis against 10 mM PBS, pH 7.3, before further characterization.
MDP was estimated by a modification of the method of Levvy and McAllen for
the determination of hexosamines [18]. Extent of maleylation was quantified
using trinitrobenzenesulfonic acid (TNBS) as described by Habeeb [19]. A
conjugate with a 15:1 molar ratio of MDP to protein was used in these studies
based on the affinity of the conjugate toward the receptor system as well as the
amount of MDP available for bio-efficacy. Endotoxin contamination in the
conjugate was detected using an endotoxin detection kit according to the
manufacturer’s instructions.
Binding of 125I-MBSA-MDP with peritoneal
macrophages
Plated peritoneal Mf were washed once with ice-cold RPMI medium contain-
ing 1 mg/mL of BSA (medium A) before starting the assay. For binding
experiments, cells were incubated in 1 mL of ice-cold medium A containing
different concentrations of 125I-MBSA-MDP (specific activity 526 cpm/ng
protein) in the presence or absence of excess MBSA (300 µg/mL) at 4°C for 3 h.
Unbound material was removed by washing cells three times with chilled PBS
containing 1 mg/mL BSA and once with PBS. Washed cells were dissolved in
400 µL of 0.1 N NaOH, and the cell-associated radioactivity was measured by
placing an aliquot in a g-radiation counter. Protein content of the cell lysates
was estimated by the bicinchoninic acid (BCA) method [20]. Specific binding of
125I-MBSA-MDP with macrophages was determined by subtracting the values
for binding of 125I-MBSA-MDP in the presence of excess MBSA from the total
binding.
Kinetics of uptake and degradation of
125I-MBSA-MDP with peritoneal macrophages
Seeded cells were washed and incubated in prewarmed medium A containing
13 µg/mL of 125I-MBSA-MDP for indicated periods at 37°C. At respective time
points, the amount of the TCA-soluble (non-iodide) radioactivity released in the
medium was determined as degradation [21]. Cells were washed as described
previously to determine the cell-associated radioactivity.
Macrophage-mediated cytolysis assay
Macrophage-mediated cytolysis of the target cells was determined by measur-
ing [3H]dThd release from prelabeled target cells [22]. The cytolytic activity of
MBSA-MDP-treated J774A.1 (a murine macrophage cell line) was compared
with that of free MDP-treated cells using this assay. J774A.1 cells (2 3 105)
were treated with indicated concentrations of the free and conjugated MDP at
37°C in 5% CO2 and 95% air for 24 h. Cells were washed and co-cultured with
[3H]dThd-prelabeled B16F10 melanoma cells at a 10:1 effector-to-target ratio
for 48 h at 37°C. After incubation, the microtiter plates were centrifuged for 2
min at 250 g, and an aliquot of supernatant was assayed for radioactivity
released from the target cells. The percent specific cytolysis was calculated
using the following formula: %cytolysis 5 [(cpm treated wells 2 cpm untreated
wells)/cpm of target cells added] 3 100.
Macrophage-mediated inhibition of [3H]thymidine
incorporation by the target cells
Inhibition of [3H]dThd incorporation by the target tumor cell was measured to
determine the cytotoxic activity of peritoneal resident macrophages treated with
free or conjugated MDP [22]. Mouse peritoneal resident macrophages (2 3 105)
were incubated with indicated concentrations of the free and conjugated MDP
at 37°C in 5% CO2 and 95% air atmosphere for 24 h. Cells were washed and
cocultured with L929 fibroblast as the target cell at 10:1 effector-to-target ratio
for 48 h at 37°C and pulsed with 0.5 µCi [3H]dThd for the last 24 h of
incubation. The cells were harvested and analyzed for radioactivity incorpo-
rated. The results were expressed as percent inhibition of [3H]dThd incorpora-
tion by the target cells. Percentage inhibition was calculated as: %inhibition 5
[(cpm of untreated well 2 cpm of treated well)/cpm untreated wells] 3 100.
Estimation of soluble mediators released by
activated macrophages
Supernatants from treated and untreated peritoneal resident macrophages were
analyzed for tumor necrosis factor, interleukin (IL)-1, IL-6, IL-10, IL-12, and
PGE2, through the use of enzyme-linked immunoassays as described in the
supplied kits. The ability of macrophages to secrete reactive nitrogen interme-
diates was also analyzed by the Greiss reaction for nitrite [23].
RESULTS
Recognition of MBSA-MDP by macrophages
The data presented in Figure 1 show that when mouse
peritoneal resident Mf cells were incubated with different
Fig. 1. Binding of MBSA-MDP to mouse peritoneal resident Mf at 4°C. The
Mf (106) were incubated with indicated concentrations of 125I-MBSA-MDP
(specific activity 526 cpm/ng) for 3 h at 4°C in the absence or presence of
excess MBSA (300 µg/mL) and processed as described under Materials and
Methods. Specific binding was obtained by subtracting the values for nonspe-
cific binding from the total binding. Results are expressed as nanograms
labeled protein bound per milligram cellular protein and represents an average
of three determinations 6 SE.
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concentrations of 125I-MBSA-MDP for 3 h at 4°C, MBSA-MDP
bound to these cells with saturation kinetics. The half-maximal
binding to the cells was achieved at approximately 15 µg/mL of
125I-MBSA-MDP in the medium.
When Mf were incubated with 13 µg/mL of 125I-MBSA-MDP
at 37°C for different periods of times, the cell-associated
radioactivity reached a steady-state plateau after about 60 min,
but trichloroacetic acid (TCA)-soluble radioactivity continued
to appear in the medium, suggesting simultaneous uptake and
degradation of the drug conjugate (Fig. 2A). The amount of
radioactivity accumulated in the medium after 5 h was about
three times higher than the cell-associated radioactivity. Both
uptake and degradation of MBSA-MDP was competed by
MBSA but not by MDP (Fig. 2B). Moreover, 125I-MBSA-MDP
degradation was blocked by the lysosomotropic agent, monen-
sin (data not shown), indicating lysosomal degradation of the
conjugate after internalization.
To determine whether the uptake of MBSA-MDP was medi-
ated via the SCR, we determined the concentrations of various
negatively charged compounds required to cause 50% inhibi-
tion of the degradation of 125I-MBSA-MDP (13 µg/mL) by these
cells. The results presented in Table 1 show that relatively low
concentrations (3–7 µg/mL) of the effective competitors, viz.,
MBSA, fucoidin, polyguanylic acid (PolyG), and polyinosinic
acid (PolyI) brought about 50% inhibition of degradation of
radiolabeled conjugate. In contrast, much higher concentra-
tions (20-fold or more) of other negatively charged molecules,
namely, polyadenylic acid (PolyA), polycytidylic acid (PolyC),
and fetuin were required for inhibiting degradation to the same
extent. Similarly, binding of 125I-MBSA-MDP by the Mf were
also inhibited by the SCR ligands (data not shown).
Activation of tumoricidal properties of
macrophages
To determine the effect of MBSA-MDP treatment of Mf on their
tumoricidal properties, mouse peritoneal Mf or J774A.1 cells
were cultured in the presence of indicated concentrations of
MBSA-MDP or free MDP for 24 h, washed and co-cultured with
target cells at a ratio of 10:1 (effector:target) for a further 48 h.
About 50% lysis of the target cells was achieved (Fig. 3A)
when B16F10 melanoma cells prelabeled with [3H]dThd were
incubated with J774A.1 Mf treated with 1 µg/mL MBSA-MDP.
Treatment of the Mfs with free MDP, BSA-MDP, or MBSA at a
dose equivalent to MBSA-MDP did not show any cytolytic
activity toward the target cells. MBSA-MDP-treated peritoneal
Mf co-cultured with B16F10 melanoma cells also exhibited
similar cytolytic activity (data not shown).
To evaluate the cytotoxic efficacy of activated Mf using
L929 fibroblasts as the target, mouse peritoneal Mf were
treated with indicated concentrations of MBSA-MDP or free
MDP for 24 h, washed, and co-cultured with L929 target cells at
a target-to-effector ratio of 1:10 for another 24 h, followed by
[3H]dThd pulsing for an additional 24 h. The results presented
in Figure 3B show that 5 µg/mL of MDP inhibited about 20% of
[3H]dThd uptake by target cells, but the similar effect was
obtained by 0.1 µg/mL of MDP in the conjugated form under the
identical condition. Moreover, the cytolytic activity of the
MBSA-MDP-treated Mf toward L929 target cells was abol-
ished when these cells were incubated along with PolyG, a
high-affinity ligand for the SCR (Fig. 4).
Enhanced secretion of tumor-suppressive
cytokines by activated macrophages
To further explore the mechanism of anti-tumor activation, we
measured the levels of various soluble mediators secreted by
the Mf after treatment with MDP. Treatment of peritoneal
Fig. 2. (A) Time course of uptake and degradation of 125I-MBSA-MDP by
mouse peritoneal resident Mf at 37°C. Mf (106) were incubated at 37°C with
13 µg/mL of 125I-MBSA-MDP as in Figure 1. At indicated time intervals, the
amount of 125I-MBSA-MDP accumulated in the cells and 125I-labeled TCA-
soluble degradation products released in the medium were determined as
described in Materials and Methods. Results are the average of three
determinations 6 SE and expressed as nanograms labeled protein taken up or
degraded per milligram cellular protein. (B) Effects of MDP and MBSA on the
uptake and degradation of 125I-MBSA-MDP by mouse peritoneal resident Mf at
37°C. Mf (106) were incubated with 13 µg/mL of 125I-MBSA-MDP in presence
of either MDP or MBSA at 37°C. At indicated time intervals, supernatants and
cells were processed for degradation and cell-associated radioactivity, respec-
tively. Results are expressed as nanograms labeled protein associated with the
cells or degraded per milligram cellular protein and represents an average of
three determinations 6 SE.
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resident Mf with MBSA-MDP (equivalent to 0.25 µg/mL)
triggered twofold higher levels of TNF-a and IL-6, and 10-fold
higher levels of IL-1 when compared with that released on
treatment with free MDP (Fig. 5A). Secreted levels of PGE2
were comparable to those obtained on free MDP treatment.
MBSA-treated Mf exhibited low levels of TNF-a and IL-6 but
triggered a fivefold higher level of IL-1 compared with free
MDP. Unlike MBSA-MDP treatment, MDP in the free form
triggered the Mf suppressor cytokine, IL-10 (Fig. 5A). Signifi-
cant levels of IL-12 were detected soon after MBSA-MDP
treatment of Mf and this secretory response was detectable
even 48 h after treatment. Neither MDP nor MBSA was able to
induce IL-12 release in peritoneal resident Mf (Fig. 5A).
MBSA-MDP treatment was also able to elicit sevenfold higher
nitric oxide (NO) response than that triggered by MDP (Table
2). The enhanced secretion of cytokines by MBSA-MDP-
treated macrophages was not due to the endotoxin contamina-
tion. Endotoxin contamination in MDP in free or conjugated
form (equivalent to 0.25 µg/mL of MDP) was found to be less
than 0.03 EU through the use of a Limulus lysate endotoxin
detection kit (data not shown). The results presented in Figure
5B show that release of TNF-a, IL-6, IL-12, and NO is
significantly inhibited when the Mfs were treated with MBSA-
MDP in the presence of excess PolyG (10 µg/mL), indicating
that the SCR-mediated uptake is required for inducing secre-
tion of these cytokines.
Role of secreted metabolites in anti-tumor activity
of activated macrophages
To determine the role of NO released by Mf treated with
MBSA-MDP, cytotoxic activity of the activated Mf were
measured in the presence of aminoguanidine (20 µg/mL). The
data presented in Figure 6A shows that about 50% of the
Fig. 3. (A) Effect of free MDP and MBSA-MDP on J774A.1 Mf-mediated
B16F10 tumor cytolysis. Mf (2 3 105) were incubated with indicated
concentrations of MDP in the free form or conjugated with BSA or MBSA. After
24 h, Mf were washed and target tumor cells prelabeled with [3H]dThd were
added at a 10:1 Mf-to-target cell ratio (25,400 6 400 cpm/well). Radioactivity
released in the culture medium 48 h after addition of the target cells to Mf was
monitored. Data represented as % cytolysis are an average of three determina-
tions 6 SE. (B) Effect of MDP or MBSA-MDP treatment on anti-tumor activity of
mouse peritoneal resident Mf. Mf (2 3 105) were treated with indicated
concentrations of MDP in the free or conjugated form (MBSA-MDP) for 24 h.
Treated macrophages were washed and target L929 cells (2 3 104) were added
to the Mf monolayers and cocultured for 24 h. Cells were pulsed with [3H]dThd
(1 µCi/well) for the subsequent 24 h and radioactivity incorporated by the target
cells were measured. Total [3H]dThd incorporated by the target cells in the
absence of macrophages was 45,690 6 1200. Results are expressed as %
growth inhibition from the average of three determinations 6 SE as described in
Materials and Methods.
TABLE 1. Degradation of 125I-MBSA-MDP by Mf:
Competition by Negatively Charged Macromolecules
Effective
competitor IC50
Ineffective
competitor IC50
Fucoidin 5.5 Fetuin 1290
PolyG 3.1 PolyC 109
PolyI 3.0 PolyA 64
MBSA 7.0
Mouse peritoneal Mf were incubated with 125I-MBSA-MDP (specific activity
526 cpm/ng) at 37°C in the presence or absence of various test samples. After 5
h, supernatants were tested for the degradation product of 125I-MBSA-MDP.
IC50: effective concentration in µg/mL required for 50% inhibition of degrada-
tion of 15 µg/mL 125I-MBSA-MDP.
Fig. 4. Effect of PolyG on Mf-mediated tumor cytolytic activity. Mouse
peritoneal resident Mf (2 3 105) were treated with 0.25 µg/mL in the free or
conjugated form (MBSA-MDP) or with conjugate equivalent protein control
(MBSA) for 24 h in the presence or absence of PolyG (10 µg/mL). Treated
macrophages were washed, and [3H]dThd prelabeled target L929 tumor cells
were added at a 10:1 macrophage-to-target cell ratio (43,879 6 978 cpm/well).
Radioactivity released in the culture medium 48 h after addition of the target
cells to Mf was monitored. Data represent an average of three determina-
tions 6 SE. Radioactivity released by the cytolytic activity of untreated
macrophages was 6020 6 202 cpm.
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anti-tumor activity is blocked by aminoguanidine, a specific
inhibitor of inducible NO synthase. Similarly, antibodies against
TNF-a, IL-1, or IL-6 blocked about 50% of the cytotoxic
activity of Mf induced on MBSA-MDP treatment (Fig. 6A).
Addition of anti-TNF-a along with anti-IL-1 or anti-IL-6
further reduced the cytotoxic activity of the Mf toward the
tumor cells to 20 or 2%, respectively, whereas anti-IL-12
antibody inhibited the cytotoxic activity by about 30%. Treat-
ment with the antibodies alone or in combination did not cause
any toxic effect to either the target or the effector cells as
measured by MTT assay (data not shown).
The presence of indomethacin (IM), an inhibitor of prostaglan-
din synthase, during activation reduced the Mf-mediated
cytotoxicity to the target cells by about 80% (Fig. 6B). The
inhibition of PGE2 production along with neutralization of IL-1
or IL-6 could partially restore (,50%) the cytotoxic efficacy of
the activated Mf suggests that IL-1 or IL-6 regulates prostaglan-
din production. Moreover, the addition of anti-TNF-a antibod-
ies along with IM completely blocked Mf anti-tumor activity.
DISCUSSION
The modulation of antitumor properties of Mf by different
biological response modifiers is an area of active interest for
cancer chemotherapy. It has been shown that antitumor proper-
ties of macrophages can be activated by interferon-g, lipopoly-
saccharide, as well as MDP. Although a powerful inducer of the
antitumor activity of the Mf, MDP is quickly eliminated from
the body, thereby limiting its therapeutic utility [24–26].
Moreover, there are conflicting reports about the existence of
MDP receptor on Mf and the efficiency of the uptake process
Fig. 5. (A) Secretory status of mouse peritoneal resident Mf on treatment. Mf
(105) were treated with 0.25 µg/mL MDP in the free or conjugated form or with
conjugate equivalent protein (MBSA) control. After 24-h treatment, supernatants
were tested by ELISA for IL-1, IL-6, IL-10, IL-12, TNF-a, and PGE2 released.
Data represent the average of three determinations 6 SE. (B) Inhibition of
MBSA-MDP-mediated Mf activation by PolyG. Mf (105) were treated with
MBSA-MDP (0.25 µg/mL MDP equivalent) in the conjugated form in the absence
or presence of excess PolyG (10 µg/mL). After 24 h treatment, supernatants were
tested for IL-6, IL-12, TNF-a, and NO released by the Mf. Each cytokine
released by MBSA-MDP-treated Mf in the absence of excess PolyG were chosen
as 100%. Data represent the average of three determinations.
TABLE 2. Evaluation of NO Released by Free MDP and
MBSA-MDP-Treated Mf
Concentration Treatment NO released (µM)
0.25 µg/mL MDP ,2
MBSA-MDP 47 6 5
MBSA ,2
0.5 µg/mL MDP 17 6 3
MBSA-MDP 134 6 7
MBSA ,2
NO release was measured as described in Materials and Methods and results
are expressed as average of three determinations 6 SE.
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by the Mf [27–29]. Accordingly, different modalities have been
tried to enhance the efficacy of MDP by targeting MDP using
liposomes or soluble carrier systems based on acetylated
low-density lipoprotein or mannosylated neoglycoproteins [30–
34]. Although targeting of MDP using some carrier increased
the therapeutic efficacy of MDP, the mechanism of activation of
the tumoricidal properties of Mf is not clear.
Because SCRs are expressed primarily on Mf, they have
been exploited extensively for modulating Mf function for
various purposes by specific delivery of appropriate agents
[35–43]. In the present investigation, we made an attempt to
specifically activate the antitumor properties of Mf by delivery
of MDP. The results presented in these studies demonstrate that
MBSA-MDP binds to discrete binding sites present on the
surface of the Mf (Fig. 1). High-affinity binding led to rapid
internalization of the MBSA-MDP followed by degradation in
the lysosomes (Fig. 2A). The results presented in Figure 2B
show that uptake and degradation of MBSA-MDP by Mf is
inhibited by MBSA, suggesting that the recognition of the
conjugate by Mf is mediated through the MBSA binding site.
The data presented in Table 1 demonstrate that the degradation
of MBSA-MDP is competed by the established polyanionic
ligands of the SCR system, viz., MBSA, PolyG, PolyI, and
fucoidin but not by other polyanionic macromolecules, e.g.,
PolyC, BSA-MDP, or fetuin, suggesting SCR-mediated recogni-
tion of MBSA-MDP. Although the intracellular content of
MBSA-MDP was not measured in these studies, it is pertinent
to mention that SCR-mediated endocytosis of the drug conju-
gate leads to about 8- to 10-fold higher intracellular level of the
drug than that resulting from the same concentration of the free
drug in the medium [14].
The MBSA-MDP-mediated activation of antitumor proper-
ties of Mf was monitored on two tumor cells of non-Mf origin,
e.g., B16F10 and L929. MBSA-MDP-treated Mf exhibited
more pronounced antitumor activity against both cells by
cytotoxic and cytolytic assays than that elicited by the same
concentration of the free drug. Fifty percent lysis of the target
cells was achieved by 1 µg/mL of MBSA-MDP, the concentra-
tion at which the free MDP-treated Mf did not cause significant
antitumor activity (Fig. 3A). Furthermore, when Mf were
incubated with high concentrations of PolyG during activation
with MBSA-MDP, the antitumor activity of the macrophages
was totally abolished, suggesting that activation was due to the
high-affinity uptake of the drug conjugate through SCR-
mediated endocytosis (Fig. 4).
To understand the mechanism of macrophage activation, we
measured the secretion of different cytokines and other soluble
mediators as an indicator of the signal transduction cascade
induced by intracellular delivery of MDP to Mf through
SCR-mediated uptake of MBSA-MDP. The results presented in
this study (Fig. 5A) show that Mf treated with MBSA-MDP
induced several-fold higher secretion of TNF-a, IL-1, IL-6, and
IL-12 compared with Mf treated with MBSA or free MDP. Both
free MDP and MBSA-treated Mf, however, secreted signifi-
cantly higher levels of TNF-a, IL-1, IL-6, and PGE2 than the
untreated control. These results are consistent with the observa-
tion that maleylated BSA stimulated the secretion of TNF-a
[44, 45] and PGE2 [46]. Thus, the induced secretion of different
cytokines by MBSA-MDP-treated Mf over the free MBSA may
be due to the intracellular delivery of MDP, which is supported
by our results that enhanced secretion of these cytokines by
MBSA-MDP-treated Mf is significantly inhibited in the pres-
Fig. 6. (A) Effect of antibodies against interleukins on Mf-mediated anti-
tumor activity induced on MBSA-MDP treatment. Mouse peritoneal resident
Mf (2 3 105) were treated with MBSA-MDP containing 0.25 µg/mL MDP for
24 h. Treated mf were washed and L929 target cells (2 3 104) were added to
the Mf monolayers along with aminoguanidine (20 µg/mL) or neutralizing
antibodies to IL-1, IL-6, IL-12, or TNF (20 µg/mL) alone or in various
combinations. After 24 h of co-culture, cells were pulsed with 1 µCi/well
[3H]dThd for 24 h and processed as described in Materials and Methods.
Results are expressed as % growth inhibition and are the average of three
determinations 6 SE. (B) Effect of selective co-neutralization of PGE2 and
interleukins on Mf-mediated anti-tumor activity induced on MBSA-MDP
treatment. Mouse peritoneal resident Mf (2 3 105) were treated with
MBSA-MDP containing 0.25 µg/mL of MDP for 24 h. Treated macrophages
were washed and L929 target cells (2 3 104) were added to the Mf monolayers
along with neutralizing antibodies to IL-1, IL-6, or TNF-a (20 µg/mL) in various
combinations with indomethacin (20 µg/mL). After 24 h, cells were pulsed with
1 µCi/well [3H]dThd for a subsequent 24 h and processed. Mf alone
incorporated 1128 6 80 cpm. Total [3H]dThd incorporated by the target cells in
the absence of Mf was 30,300 6 2052. Results are expressed as % growth
inhibition from the average of three determinations 6 SE.
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ence of excess PolyG (Fig. 5B). The results presented in our
study (Table 2) also demonstrate that MBSA-MDP-treated Mf
induced the overproduction of NO in comparison with the cells
treated with MBSA or free MDP. Recently, it has been shown
that MBSA in combination with interferon-g promote the
release of NO through inducible NO synthase, but MBSA alone
does not induce NO production, as also observed in our study
[47]. Our results showing that cytotoxic activity of MBSA-MDP-
treated Mf is inhibited by aminoguanidine, a specific inhibitor
of inducible nitric oxide synthase [48] suggest the possibility of
NO production by the activated Mf through the induction of
inducible NO synthase. TNF-a, IL-1, IL-6, and NO are known
to have tumoricidal activity [49–52] and the secretion of these
molecules is also regulated by PGE2 [53, 54]. Moreover, it was
evident from our study that free MDP stimulates the secretion of
IL-10, which has suppressor activity [55, 56]. In contrast,
MBSA-MDP did not induce the secretion of IL-10. Thus, the
antitumor activity induced by MBSA-MDP not only promotes
the secretion of cytotoxic cytokines but also inhibits the
secretion of cytokines that have Mf suppressor activity.
To determine the role of the cytokines secreted by the
activated Mf, we measured the cytotoxic activity of MBSA-
MDP-treated Mf in the presence of respective antibodies to
each cytokine alone or in combination. The results presented in
Figure 6A show that antibodies against TNF-a, IL-1, and IL-6
inhibit about 50% of the cytotoxic activity but complete
inhibition was observed when anti-TNF-a antibodies were
added along with anti-IL-1 or -IL-6. Similarly, inhibition of NO
production by aminoguanidine also significantly reduced the
cytotoxic activity of MBSA-MDP-treated Mf. It was, therefore,
concluded that the antitumor activity induced in Mfs on
treatment with MBSA-MDP was primarily mediated through
TNF-a, IL-1, IL-6, and NO. TNF-a affected macrophage
effector response probably by itself and through positive
regulation of IL-6 and IL-1.
PGE2 seems to have a regulatory role in the induction of
cytotoxic activity in macrophages through its role as inducer or
suppressor of soluble mediators of Mf origin. In this investiga-
tion, we used IM, an inhibitor of prostaglandin biosynthetic
pathway [57], to determine the role of prostaglandins in
activation of Mf tumoricidal properties . Our results show that
antitumor properties of the Mf was inhibited by IM treatment
(Fig. 6B). This may be due to the down-regulation of TNF-a
secretion, thereby regulating the secretion of IL-1 and IL-6 [58,
59]. These observations are further supported by the fact that
simultaneous treatment of Mf with IM and anti-TNF-a (to
neutralize residual TNF-a) totally inhibited the cytotoxic
activity of the activated Mf, suggesting the role of TNF-a in the
activation of tumoricidal activity of Mf. It is also possible that
prostaglandins down-regulate the secretion of NO, which was
shown to have antitumor activity. Moreover, inhibition of PGE2
production along with the neutralization of IL-1 or IL-6
partially restored the cytotoxic activity of the activated Mf,
indicating that IL-1 acts upstream of the prostaglandin synthe-
sis pathway.
In conclusion, our data demonstrate that it is possible to
augment the antitumor efficacy of Mf through the delivery of
MDP via the SCR-mediated endocytic pathway. Intracellular
delivery of MDP modulates the signal transduction pathway in
Mf, leading to secretion of cytokines that are known to activate
antitumor activity. The enhanced tumoricidal ability of Mf
treated with MBSA-MDP is likely to be mediated by the action
of TNF, IL-6 in conjunction with IL-1, and NO. We have also
demonstrated that the expression of SCR as well as Mac1
remained unaltered under all the treatment conditions (data not
shown). Thus, MBSA-MDP-activated Mf are functionally nor-
mal in terms of their SCR activity, indicating the possible use of
this general modality for the treatment of cancer.
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